此外，公司通过优化管理、迭代工艺，产品单位成本降低、毛利率提升，销售费用率也明显下降，综合 以上积极因素，公司盈利效率大幅改善。 公告中提到，公司业绩变动原因主要是公司核心产品泰它西普、维迪西妥单抗国内销售收入快速增长， 成为业绩核心增长引擎；同时，公司成功达成与Vor Biopharma的重磅授权合作，技术授权收入大幅增 加。 近日，荣昌生物发布公告称，根据2025年度业绩快报显示，公司实现营业总收入32.51亿元，同比增加 89.36%；归母净利润7.09亿元，归母净利润由亏损转为盈利。 ...

Core Viewpoint - Nomura's report indicates that WuXi Biologics has announced a profit forecast, expecting a 16.7% year-on-year revenue growth to 21.8 billion yuan in 2025, slightly above the market expectation of 21.5 billion yuan [1] Revenue and Profit Forecast - The gross margin is expected to improve by 5 percentage points year-on-year to 46%, also exceeding the market expectation of 43% [1] - Net profit and profit attributable to shareholders are projected to grow by 45.3% and 46.3% year-on-year, reaching 5.7 billion yuan and 4.9 billion yuan, respectively, surpassing market expectations of 4.8 billion yuan and 4.4 billion yuan [1] - For the second half of 2025, revenue is estimated to grow by 17.2% year-on-year to 11.8 billion yuan, with profit growth of 38%, both exceeding market expectations [1] Management Insights - Management attributes the growth to optimistic performance in research service revenue and an increase in projects entering later stages due to enhanced service capabilities [1] Target Price Adjustment - Nomura has raised its target price from 37.36 HKD to 50.54 HKD, maintaining a "Buy" rating [1]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is anticipated to grow to approximately RMB 10,638 million, representing a year-on-year increase of about 25.5% [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is anticipated to grow to approximately RMB 10,638 million, representing a year-on-year increase of about 25.5% [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation expenses, foreign exchange gains and losses, equity investments, asset disposals, restructuring gains and losses, and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is expected to rise to approximately RMB 10,638 million, reflecting a year-on-year growth of about 25.5% [1] - Profit attributable to equity shareholders is anticipated to grow by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation expenses, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and losses, and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics (02269.HK) reported a 16.1% year-on-year increase in revenue for the six months ending June 30, 2025, reaching RMB 9,953.2 million [1] Financial Performance - Gross profit increased by 27.0% year-on-year to RMB 4,252.9 million, with a gross margin improvement of approximately 3.6% [1] - Net profit attributable to the company owners rose by 54.8% to RMB 2,756.6 million, while net profit increased by 56.0% to RMB 2,339.3 million [1] Order Backlog - The total amount of uncompleted orders as of June 30, 2025, increased to USD 20.3 billion, which includes uncompleted service orders of USD 11.4 billion and uncompleted potential milestone payment orders of USD 9.0 billion [1] - The total amount of uncompleted orders over the next three years as of June 30, 2025, increased to USD 4.2 billion [1]